Vistin Pharma ASA: Invitation to Q4 2021 conference call
Oslo, Norway, 8 February 2022 Vistin Pharma ASA will release its fourth quarter 2021 results on Thursday 17th of February 2022....
Year: 2022
Route 92 Medical® Announces First Patient Enrollment in the SUMMIT MAX Pivotal Clinical Trial for the Monopoint® Reperfusion System
SAN MATEO, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a private medical technology company dedicated to...
Eyenovia Concludes Type A Meeting with FDA Related to MydCombi™ NDA Resubmission
No additional clinical work required; NDA resubmission anticipated in Q3 2022NEW YORK, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc....
Healx and Ovid Therapeutics to Enter Strategic Partnership
– Ovid to License Gaboxadol to Healx – – Healx to Explore Gaboxadol in Combination Therapies for Fragile X, Other...
Hyperfine Appoints Chip Truwit, M.D. as Senior Medical Director
Creators of the world’s first FDA-cleared portable MRI scales executive team for its next phase of development Dr. Chip Truwit,...
NextCure to Present at 11th Annual SVB Leerink Global Healthcare Conference
BELTSVILLE, Md., Feb. 08, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and...
Beyond Air® Announces Participation at Upcoming Investor Conferences in March 2022
GARDEN CITY, N.Y., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical...
Soleno Therapeutics to Participate in the BIO CEO & Investor Conference
REDWOOD CITY, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing...
Salarius Pharmaceuticals to Participate in the 2022 BIO CEO & Investor Conference
HOUSTON, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines...
Palisade Bio (Nasdaq: PALI) to Announce Adhesions Clinical Data at SAGES 2022 Annual Meeting
Incidence and Severity of Post-Surgical Intraabdominal Adhesions following Bowel Resection Surgery and Treatment with Enteral Protease Inhibitor LB1148CARLSBAD, Calif., Feb....
Frontier Medicines Announces Renowned Physician Scientist Piro Lito, M.D., Ph.D., Joins Scientific Advisory Board
SOUTH SAN FRANCISCO, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company seeking to unlock...
GelStat Announces $5 Million Public Offering Under Regulation A+
GelStat Corporation Has Been Qualified by the SEC for a Regulation A+ Public OfferingSTUART, Fla., Feb. 08, 2022 (GLOBE NEWSWIRE)...
Werewolf Therapeutics to Present at the SVB Leerink Global Healthcare Conference
CAMBRIDGE, Mass., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical...
Akero Therapeutics Completes Enrollment of Phase 2b HARMONY Study in Pre-Cirrhotic NASH Patients
SOUTH SAN FRANCISCO, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for...
Gain Therapeutics Presents Preclinical Data on its Structurally Targeted Allosteric Regulators in GBA1 Gaucher Disease at the WORLDSymposium 2022
Study results demonstrate GBA1-targeted allosteric regulators increase GCase protein levels, reduce the production of inflammatory cytokines, and improve key lysosomal...
iCAD to Present at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
NASHUA, N.H., Feb. 08, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer...
Ocuphire Completes Enrollment in MIRA-3 Pivotal Phase 3 Clinical Trial for Nyxol® in RM and Announces Two Upcoming Medical Conference Presentations
Completed enrollment ahead of schedule in second Phase 3 FDA registration trial for Nyxol in RM (MIRA-3) with top-line results...
Recce Pharmaceuticals Announces Positive Safety Data from Third Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327
Highlights: Seven subjects in cohort three intravenously dosed; RECCE® 327 at 500mg indicating to be safe and well tolerated Minimum...
Noema Pharma to Host Key Opinion Leader Webinar on Trigeminal Neuralgia “Trigeminal Neuralgia? You are not alone”
Friday, February 11th 2012 - 12 pm EST / 6 pm CET Featuring Dr. Joanna Zakrzewska from University College London...
Aleafia Health to Announce Fourth Quarter 2021 Results
TORONTO, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Aleafia Health Inc. (TSX: AH, OTCQX: ALEAF) (“Aleafia Health” or the “Company”) will...
